Description: Jazz Pharmaceuticals Public Limited Company, a specialty biopharmaceutical company, engages in the identification, development, and commercialization of pharmaceutical products for various medical needs in the United States, Europe, and other countries. The company's products include Xyrem for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia; Prialt for the management of severe chronic pain; and FazaClo LD and FazaClo HD, which are orally disintegrating clozapine tablets for the resistant schizophrenia treatment. It also provides Luvox CR to treat obsessive compulsive disorder; Versacloz oral suspension; Caphosol to treat oral mucositis; Quadramet for the treatment of pain in patients whose cancer has spread to the bones; ProstaScint for imaging the extent and spread of prostate cancer; Niravam for the treatment of generalized anxiety and panic disorders; and Parcopa for the symptoms associated with idiopathic Parkinson's disease treatment. In addition, the company offers Collatamp, a surgical implant impregnated with the antibiotic gentamicin; Fomepizole to treat ethylene glycol poisoning; Kidrolase for treating ALL, Leukaemic meningitis, and non-Hodgkin's lymphoma; Xenazine to treat movement disorders associated with Huntington's chorea and hemiballismus; and Custodiol, a ready to use solution used in organ transplantation. Further, it develops Asparec, a pegylated recombinant Erwinia asparaginase that is in Phase I clinical trials for the treatment of patients with ALL with E. coli asparaginase hypersensitivity; and Leukotac, an anti-CD25 monoclonal antibody is in Phase III clinical trials for the treatment of steroid-refractory acute graft vs. host diseases. The company markets its products through its sales representatives, distributors, and wholesalers, as well as through third party vendors. Jazz Pharmaceuticals Public Limited Company is headquartered in Dublin, Ireland.
Home Page: www.jazzpharma.com
JAZZ Technical Analysis
Waterloo Exchange
Dublin,
4
Ireland
Phone:
353 1 634 7800
Officers
Name | Title |
---|---|
Mr. Bruce C. Cozadd | Co-Founder, Chairman & CEO |
Mr. Daniel N. Swisher Jr. | Pres & COO |
Ms. Renee D. Gala | Exec. VP & CFO |
Dr. Robert Iannone M.D. | Exec. VP and Global Head of R&D |
Ms. Patricia Carr | Sr. VP & Chief Accounting Officer |
Dr. Finbar Larkin Ph.D. | Sr. VP of Technical Operations |
Ms. Andrea N. Flynn Ph.D. | VP & Head of Investor Relations |
Ms. Neena M. Patil J.D. | Exec. VP & Chief Legal Officer |
Dr. George Christopher Eliades Ph.D. | Sr. VP of Corp. Devel. & Chief Transformation Officer |
Ms. Heidi Manna | Sr. VP & Chief HR Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
GIC Sector: | Health Care |
---|---|
GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
GIC Industry: | Pharmaceuticals |
GIC Sub-Industry: | Pharmaceuticals |
Forward PE: | 9.1075 |
---|---|
Trailing PE: | 0 |
Price-to-Book MRQ: | 3.6126 |
Price-to-Sales TTM: | 2.6873 |
IPO Date: | 2007-06-01 |
Fiscal Year End: | December |
Full Time Employees: | 3200 |